The purpose of this comparative trial was to assess the ef®cacy and safety of transurethral (MUSE TM ) vs. intracavernous Alprostadil in the diagnostic evaluation of male impotence. From this point of view, diagnostic intracavernous Alprostadil is clearly preferable to MUSE TM especially in the evaluation of the relaxant capacity of the cavernous smooth musculature as MUSE TM resulted in only 10% of 103 pts. in a complete rigidity, compared to 48% after i.c. Alprostadil. Therefore I agree with the comment that MUSE TM should be considered more an intercourse facilitator than an erection inducer.
The target of this article was not to accuse MUSE TM as an ineffective therapy, mentioned in this comment. If the author of this comment would have thoroughly read through this paper he could not have overlooked the statement in the discussioǹ`a nd these patients in whom MUSE TM works reliably at home are very satis®ed with this new therapeutic option''. But exactly this therapeutic reliability is the crucial point of MUSE TM compared to i.c. Alprostadil. Both, acceptance and satisfaction of any therapy are best assessed by the drop-out rates in long-term clinical trials. So, for example, in the MUSE TM European Multicenter Study with 249 patients involved, the drop-out rate after 15 months was 75%! The respective drop-out rates of the i.c. Alprostadil Alfadex (Edex TM ) European Multicenter Study with 162 pts. involved, were 54% after 24 months and 67% after 48 months. The comparative numbers of the Alprostadil-Sterile Powder (Caverject TM ) European Study with 848 pts. were similar for the 18 months drop-out rate and both multicentre trials with i.c. Alprostadil in more than 1000 pts. clearly demonstrated that also in home-use i.c. Alprostadil shows a considerably higher acceptance in long-term follow up than MUSE TM . This is, by the way, also re¯ected by the tremendously low prescription re-®ll rates of MUSE TM both, in the US as well as in the own hands with only 20% of continuers in more than 150 pts. to whom MUSE TM was offered for home-use.
These data from prospective multicentre trials as well as the own comprehensive experiences clearly prove evidence on the superiority of i.c. Alprostadil against MUSE TM also in long-term use and not the opposite as it is claimed in this comment article.
A second important issue of the comment is the rate of urethral bleeding. The author argues that the urologist, in this special case the author of the article himself, is not familiar with the correct technical application of MUSE TM resulting in``such a high number of patients with urethral bleeding after MUSE TM ''. This statement is surprising and at the same time ridiculous and indicates, that he is not updated in the recent MUSE TM -data. So, for example, the rate of urethral bleeding in the European Multicenter Study with MUSE TM was 6% at home use in the 12 months extension phase, 5.1% in the 3 months US-phase published by Padma-Nathan in the NEJM 1997 (ref. 22) and 5% for 2595 patients reported by Spivack et al (ref. 29) . The encountered urethral bleeding rate in the present diagnostic trial was 4.8% in 103 pts. and was therefore below the urethral trauma rate in home use.
In this way the statement in this comment, that urethral bleeding after MUSE TM application has something to do with``physician administration'' is disproven by the published and reported MUSE TM -data of the several studies and challenges the scienti®c value of this comment.
At any rate the several prospective studies with i.c. and transurethral (MUSE TM ) Alprostadil as well as the own comprehensive experiences have convincingly proven the superiority of sel®njection therapy and MUSE TM represents a reliable and satisfying therapeutic alternative in about 25% of the impotent males. This is also re¯ected by the low re®ll prescription rates of MUSE TM . The sequelae of the 5±6% rate of urethral trauma in home-use, encountered in all the studies with MUSE TM cannot ®nally be estimated with regard to the potential for urethral strictures. In this connection we should keep in mind that it frequently takes a couple of years from the urethral trauma to the manifestation of a clinically relevant urethral stricture. This issue should be discussed in 3±5 years and up to this time, all the reassurances, that MUSE TM does not cause any urethral strictures are bare of any scienti®c basis.
